following side effects
taking bevacizumab
check
doctor
nurse
abdominal pain
vomiting
anorexia
constipation
diarrhea
stomatitis
dyspepsia
gastrointestinal hemorrhage
flatulence
dry mouth
colitis
constipation
nauseavery
upper aerodigestive tract hemorrhagefrequency
intestinal obstruction
intestinal necrosis
mesenteric venous occlusion
ileus
anastomotic ulceration
gastrointestinal perforation
wound dehiscence
intra-abdominal abscesses
tracheoesophageal fistulae
te fistulas
bevacizumab maintenance phase of the study in the context of persistent esophagitis
other cases of te fistula
other lung
esophageal cancer studies
using bevacizumab
chemotherapy
concurrent radiation treatment
incidence of gastrointestinal perforation
gastrointestinal perforation
fistula formation
intraabdominal abscess
patients with colorectal cancer
patients with non-small cell lung cancer
nsclc
receiving bevacizumab
hypertension
hypotension
deep vein thrombosis
congestive heart failurefrequency
arterial thromboembolic events
including
cerebrovascular accident
stroke
myocardial infarction
transient ischemic attack
angina
fatal arterial thrombotic events
cerebral ischemia
supraventricular tachycardia
non-serious hemorrhagic events
risk factors for the development of arterial thromboembolic events
history of arterial thromboembolism
bevacizumab exposure
age years
bevacizumab therapy
events
higher rate in these high-risk groups
study
rate of congestive heart failure
nci-ctc grade
bevacizumab
paclitaxel arm
control arm
patients
receiving anthracyclines
rate of chf
bevacizumab
treated patients
patients
receiving paclitaxel
congestive heart failure
patients
relapsed acute leukemia
non-fda
indication
receiving bevacizumab
concurrent anthracyclines in a single arm study
safety of continuation
resumption of bevacizumab in patients with cardiac dysfunction
dizziness
sensory neuropathy
confusion
abnormal gait
cns hemorrhage
cerebrovascular ischemiarare
brain-capillary leak syndrome
reversible posterior hyponatremia
hypertensive encephalopathyfrequency
dysgeusia
rpls
neurological disorder
hypertension
fluid retention
cytotoxic effects of immunosuppressive drugs on the vascular endothelium
syndrome
headache
seizure
lethargy
confusion
blindness
neurologic disturbances
severe hypertension
diagnosis
onset of symptoms
hours
year after initiation of bevacizumab
magnetic resonance imaging
diagnosis of rpls
leukopenia
neutropenia
thrombocytopeniafrequency
hemorrhagic events
pancytopenia
febrile neutropenia
hemoglobin
anemia
prothrombin time prolongations
infection with severe neutropenia
postmarketing reports
gallbladder perforation
hyperglycemia
hypomagnesemia
hyponatremia
hypoalbuminemia
weight loss
hypokalemia
bilirubinemiafrequency
increased blood potassium
decreased blood phosphorus
increased blood alkaline phosphatase
myalgia
bone pain
painpostmarketing reports
osteonecrosis of the jaw
frequency
ureteral stricture
upper
respiratory infection
fatal hemoptysis
epistaxis
dyspnea
frequency
pulmonary hypertension
fatal pulmonary hemorrhage
nasal septum perforationcommon
voice alteration
patients with recent hemoptysis
tsp of red blood
bevacizumab
study
bevacizumab-treated patients with squamous cell histology
bevacizumab-treated patients with histology
squamous cell
fatal pulmonary hemorrhage
none of the patients
receiving chemotherapy
study
rate of pulmonary hemorrhage
requiring medical intervention for the paclitaxel
carboplatin
bevacizumab arm
paclitaxel
carboplatin
arm
deaths
pulmonary hemorrhage
investigators in the paclitaxel
carboplatin
bevacizumab arm
paclitaxel
carboplatin
arm
serious hemorrhagic events
massive hemoptysis without a history of minor hemoptysis during bevacizumab therapy
kidney biopsy
patients with proteinuria
findings
thrombotic microangiopathy
study
patients age
older receiving carboplatin
paclitaxel
bevacizumab
greater relative risk for proteinuria
younger patients
proteinuria
nephrotic syndrome
lacrimation increasedpostmarketing reports
cases of serious ocular adverse reactions
been reported following
been reported following unapproved intravitreal use of this drug
vials
administration
reactions
infectious endophthalmitis
intraocular inflammation
sterile endophthalmitis
uveitis
vitreitis
retinal detachment
retinal pigment
intraocular pressure
intraocular hemorrhage
vitreous hemorrhage
retinal hemorrhage
conjunctival hemorrhage
reactions
various degrees of visual loss
including
permanent blindness
reduction in macular edema after treatment
anatomic changes at the fovea
visual hallucinations
alopecia
rash/desquamation
skin ulcerfrequency
exfoliative dermatitis
skin discolorationpostmarketing reports
necrotizing fasciitis
asthenia
pain
fatigue
headache
peripheral edema
taste disorder
infection with an unknown ancuncommon
nongastrointestinal fistula formation
infection without neutropeniafrequency
mesenteric venous occlusion
syncope
dehydration
somnolence
polyserositis
polyserositis
frequency
sepsis
wound healing complications
urinary tract infection
positive assays for treatment-emergent anti-bevacizumab
black, tarry stools
bleeding gums
body aches
pain
burning
tingling
numbness
pain in the hands
arms
feet
legs
chest pain
discomfort
chills
cloudy urine
convulsions
cough
cracks in the skin
decreased urine output
breathing
dilated neck veins
dizziness
faintness
lightheadedness
getting
lying
sitting position
ear congestion
extreme fatigue
fever
irregular breathing
irregular heartbeat
lack
loss of strength
lightheadedness
loss of appetite
loss of heat from the body
loss of voice
mood changes
nasal congestion
nervousness
pain
pain
redness
swelling in the arm
leg
difficult urination
red spots on the skin
pounding in the ears
rapid breathing
redness
runny nose
sensation of pins
needles
fast heartbeat
sore throat
sores on the skin
sores
ulcers
white spots on the lips
mouth
stabbing pain
sunken eyes
sweating
swelling of the face
fingers
feet
lower legs
swelling
inflammation of the mouth
swollen glands
thirst
tightness in the chest
trouble breathing
unusual bleeding
bruising
unusual tiredness
weakness
vomiting of blood
material
coffee grounds
bloody diarrhea
weight gain
wrinkled skin
yellow skin
stomach pain
tenderness
bone pain
difficulty with swallowing
fainting
severe constipation
severe vomiting
back pain
blisters
blurred vision
coma
confusion
dizziness
drowsiness
headache
increased thirst
muscle pain
cramps
open sores
pale skin
bloody mucus
unexplained nosebleeds
hoarseness
sudden weakness in the arms
legs
severe chest pain
voice changes
acid
sour stomach
belching
bloody nose
change in taste
taste
change
walking
balance
clumsiness or unsteadiness
diarrhea
dry mouth
excess flow of tears
hair loss
heartburn
indigestion
stomach discomfort
pain
thinning of the hair
weight loss